Sep 05, 2019 What Is a Retirement Buyout? | Finance - Zacks A retirement buyout is a form of early retirement package that employers occasionally offer workers. Typically, they are given to older workers already nearing retirement. Buyouts amount to ATRS | Expert Financial Analysis and Reporting | Smith on ... Antares’ stock promptly dropped 38% from $3.73 to $2.32 after the Company alerted investors to an issue with the Xyosted […] Antares: AMAG Submits Supplemental New Drug Application to FDA for Makena® Auto-Injector for Subcutaneous Use: (Antares (ATRS, Buy, $2.86)
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. ATRS: Antares Pharma Inc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for Antares Pharma Inc from Zacks Investment Research
26 Nov 2018 Antares Pharma, Inc. (NASDAQ:ATRS) reported third quarter results on An increase in stock compensation expense also contributed to the
Aeterna Zentaris Inc () Stock Market info Recommendations: Buy or sell Aeterna Zentaris stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Aeterna Zentaris share forecasts, stock quote and buy / sell signals below.According to present data Aeterna Zentaris's AEZS shares and potentially its market environment have been in bearish cycle last 12 months Antares Pharma: 1Q Earnings Snapshot | MarketScreener EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported a loss of $2.4 million in its first quarter. On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 1 cent.. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. 28 ETFs with Antares Pharma, Inc. (ATRS) exposure | ETF.com Antares Pharma, Inc. is a company in the U.S. stock market and it is a holding in 28 U.S.-traded ETFs. ATRS has around 5.7M shares in the U.S. ETF market.
By John Vandermosten, CFA NASDAQ:ATRS READ THE FULL ATRS RESEARCH REPORT Antares Pharma, Inc. (NASDAQ:ATRS) reported third quarter results on November 6th posting revenue growth of 19% and achieving a quarterly sales record for the company. Earnings loss was limited to a penny. Highlights for the quarter and quarter to date include FDA approval of Xyosted, ATRS - Antares Pharma News - Barchart.com Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") ("the Company") today announced that the Company's social media campaign for XYOSTED, has been honored … ATRS Antares Pharma, Inc. Stock Quote - Stock Screener Antares Pharma Inc (ATRS) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com Mar-11-19 10:35AM AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study Zacks